Weijiao Du

Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Journal: Scientific reports

Published: October 06, 2025

Integrating WGCNA and machine learning algorithm to identify ACSM5 as a prognostic biomarker and therapeutic target for predicting immunotherapy efficacy in non-small cell lung cancer.

Integrating WGCNA and machine learning algorithm to identify ACSM5 as a prognostic biomarker and therapeutic target for predicting immunotherapy efficacy in non-small cell lung cancer.

Journal: Translational cancer research

Published: July 25, 2025

Examining the spatial distribution of tumor-infiltrating immune cells in patients with stage I to IIIA LUAD.

Examining the spatial distribution of tumor-infiltrating immune cells in patients with stage I to IIIA LUAD.

Journal: Journal of leukocyte biology

Published: August 14, 2023

The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma.

The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma.

Journal: The Journal of pathology

Published: April 27, 2023

Vemurafenib for BRAF V600-mutant Erdheim-Chester disease presenting with bilateral orbital involvement.

Vemurafenib for BRAF V600-mutant Erdheim-Chester disease presenting with bilateral orbital involvement.

Journal: Clinical case reports

Published: April 21, 2023

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report.

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report.

Journal: Gland surgery

Published: July 13, 2022

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: April 03, 2022

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Journal: Cancer biology & medicine

Published: August 11, 2021

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification.

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification.

Journal: Clinical case reports

Published: February 27, 2021

Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.

Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.

Journal: Thoracic cancer

Published: October 06, 2020

Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment

Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: November 24, 2017

Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: February 27, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026